1. Catch up on your free data!

    Over recent weeks we’ve covered loads of different data stories here on our blog and have given away free data with each of them. We thought it might be helpful to provide a quick recap, and links to help you collect any of the free data sets you might have missed out on. We reported […]

  2. Top antibodies used to understand prostate cancer

    Last week we reported on our brand new text mining technology developed by our team here at CiteAb. Today we’re looking at some very specific data we can access as a result of this new technology – insights into the antibodies used in prostate cancer research. CiteAb developer Matt Helsby said: “Using this new text […]

  3. New text mining tech gives autophagy insights

    We recently told you that we have some tech updates in the pipeline – and today we are going to speak to one of our developers, Matt Helsby, to show you a new piece of tech we’ve created. So Matt, what’s new? “Hi there! Today we’re launching an update to our text mining technology which […]

  4. Fake antibodies cause stir in Chinese market

    Last week we reported on the continued fast paced growth of the Chinese antibody market, and mentioned that this has not been without its perils. Today we’re going to take a look at the lucrative market for fake research reagents that has arisen in China and was recently exposed by science journal Nature. Nature reports […]

  5. Chinese antibody market powers ahead

    Today we return to our first ever data report, released three years ago, when we claimed that China was a market no supplier could ignore, and we look at new data to see whether our predictions came true. Back in 2014 we stated that ‘the data suggests that China is set to claim the lion’s […]

  6. New team members at CiteAb

    We’re excited to be welcoming three new people to the CiteAb team – two product managers and a developer. Alicia Cooper and Rebecca Sadler join us as product managers as CiteAb continues to grow and offer ever more complex data sets and market reports. Rebecca graduates from her biology degree at the University of Bath […]

  7. First look at the global chemical probes market

      We recently announced that our team here at CiteAb has expanded our platform to cover multiple reagent types, and today we’re taking a first look at some of our new data. The inhibitors and activators used by life scientists to investigate cellular processes are collectively termed as ‘chemical probes’. They provide vital tools for […]

  8. We’re working with the GBSI to improve ICC antibody validation

    Our founder, Dr Andrew Chalmers, is leading an Antibody Validation Working Group for the Global Biological Standards Institute (GBSI) focused on improving the validation of antibodies used for ICC. The group is one of nine created by the GBSI with the aim of creating a series of antibody validation guidelines for each of the most […]

  9. What are the most important antibody targets for immunocytochemistry?

    New to our series of blogs on antibody research applications, today we are exploring the top targets for ICC, or immunocytochemistry. ICC is the staining and microscopic examination of cells, which are often grown in culture. This is not to be confused with immunohistochemistry (IHC), which involves the staining of tissues with their normal organisation […]

  10. CiteAb: now more than just antibodies!

    Here at CiteAb we have recently developed our technology so that we can now collate data on multiple reagent types – not just antibodies. This means we can now give a picture of the global market for different types of reagent, in the same way that we have for antibodies. Our founder, Dr Andrew Chalmers, […]